Despite the slightly warmer weather and longer periods of sunshine, we are still in the depths of cold and flu season, a ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

“Watched my baby with a tube down his throat for eight days and wasn’t sure if I was ever going to hold him again,” Elliot’s ...

New figures show the number of babies admitted to hospital with respiratory viruses has trebled in just a year, according to ...

What are the symptoms of RSV and who is eligible for a vaccine? - RSV might at first seem like a cold but it can quickly ...

covering the critical winter RSV season. Uptake of the nirsevimab program so far in Ireland has been high, with 83 percent of eligible infants receiving the treatment. These results have spurred ...

leaving vulnerable populations – infants, toddlers, and the elderly – at high risk of severe infection. There are currently no approved treatments for the underlying RSV infection.

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...

7. New RSV prevention options for infants and pregnant mothers A new RSV prevention option for infants was introduced in 2023: the monoclonal antibody treatment Beyfortus (nirsevimab). This shot is ...

leaving vulnerable populations – infants, toddlers, and the elderly – at high risk of severe infection. There are currently no approved treatments for the underlying RSV infection," said John ...